March Biosciences Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for MB-105 in Relapsed/Refractory CD5-Positive T-Cell Lymphoma

HOUSTON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-105, the Company’s first-in-class autologous CD5-targeted CAR-T cell therapy, in development for relapsed/refractory CD5-positive T-cell lymphoma.

The RMAT designation was granted based on data from March Bio’s ongoing multi-center Phase 2 clinical trial (NCT06534060). Preliminary findings from the safety run-in cohort suggest evidence of clinical activity with a manageable safety profile in a patient population with a significant unmet medical need. Initial results from this cohort will be presented at the American Society of Hematology 2025 Annual Meeting, with additional updates anticipated in 2026. The company plans to engage with the FDA on next steps to support an expedited development and review pathway for MB-105.

RMAT designation was established to expedite the development and review of regenerative medicine therapies for serious or life-threatening diseases where early clinical evidence indicates potential to address unmet medical need. The designation provides all the benefits of the FDA’s Breakthrough Therapy and Fast Track programs, including enhanced and frequent interactions with the Agency throughout development, and eligibility for expedited review mechanisms such as rolling and priority review.

“The FDA’s RMAT designation further validates MB-105’s potential to address a critical unmet medical need for patients with relapsed/refractory T-cell lymphoma, who face a median survival of only six months with current therapies,” said Sarah Hein, Co-Founder and Chief Executive Officer of March Biosciences. “We are encouraged by the responses observed to date and look forward to working closely with the FDA to advance MB-105 as efficiently as possible.”

March Bio will explore clinical and commercial development outside the United States and engage with regulators to define the most efficient path forward as data mature.

About MB-105
MB-105 is a potential first-in-class autologous CD5-targeted CAR-T cell therapy in development for CD5-positive hematologic malignancies, including T-cell lymphoma (TCL), T-cell acute lymphoblastic leukemia (T-ALL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). The therapy employs a proprietary CAR design that enables selective targeting of malignant cells and streamlined manufacturing without additional genetic manipulation. MB-105 has received Orphan Drug Designation and the Regenerative Medicine Advanced Therapy designation from the FDA for the treatment of relapsed/refractory CD5-positive TCL. The multicenter Phase 2 trial (NCT06534060) is enrolling at twelve sites across the United States.

About March Biosciences
Houston-based March Biosciences, launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital, Texas Children’s Hospital), is dedicated to addressing challenging cancers unresponsive to current immunotherapies. Its lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 2 clinical development for patients with relapsed/refractory T-cell lymphoma. March Biosciences is backed by leading life-sciences investors including 4BIO Capital, Mission BioCapital, TMC Venture Fund, Volnay Therapeutics, Alexandria Venture Investments, KdT Ventures, Mansueto Investments, Modi Ventures, Portal Innovations, and the Cancer Focus Fund, as well as non-dilutive support from the Cancer Prevention & Research Institute of Texas (CPRIT) and the NIH SBIR program.

Learn more at www.march.bio.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Any statement describing March Biosciences’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those projected in these forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the clinical development of MB-105, the progress of clinical trials for pipeline candidates, regulatory approvals, market demand for new therapies, competitive dynamics in the biotechnology sector, and macroeconomic conditions.

Contacts:

Corporate:
Business Communications
corporate@march.bio

Media:
Josephine Galatioto
ICR Healthcare
MarchBioPR@icrhealthcare.com